Mitochondrial dysfunction and antiretroviral nucleoside analog toxicities: What is the evidence?

Mitochondrion

Volumn 1, Issue 5, 2002, Pages 397-412

  Dagan, Tamir ^a   Sable, Craig ^a   Bray, June ^b   Gerschenson, Mariana ^c  

^a CHILDREN'S NATIONAL MEDICAL CENTER   (United States)

^b GEORGE WASHINGTON UNIVERSITY   (United States)

^c NATIONAL HEART LUNG AND BLOOD INSTITUTE   (United States)

Author keywords

Cardiovascular; Hepatic; Human immunodeficiency virus; Lactic acidosis; Lipodystrophy; Myopathies; Neuropathy; Nucleoside analog reverse transcriptase inhibitors; Pancreatitis

Indexed keywords

ABACAVIR; ANTIBIOTIC AGENT; ANTIFUNGAL AGENT; ANTIRETROVIRUS AGENT; CARBOVIR; CARNITINE; DIDANOSINE; HYDROXYUREA; INDINAVIR; ISONIAZID; LAMIVUDINE; MITOCHONDRIAL DNA; NUCLEOSIDE ANALOG; PLACEBO; PROTEINASE INHIBITOR; RIBOFLAVIN; RITONAVIR; RNA DIRECTED DNA POLYMERASE INHIBITOR; SAQUINAVIR; STAVUDINE; TUBERCULOSTATIC AGENT; ZALCITABINE; ZIDOVUDINE;

ANTIVIRAL ACTIVITY; CARDIOMYOPATHY; CENTRAL NERVOUS SYSTEM DISEASE; CONTROLLED STUDY; DATA ANALYSIS; DEGENERATIVE DISEASE; DISEASE ASSOCIATION; DISORDERS OF MITOCHONDRIAL FUNCTIONS; DOSE RESPONSE; DRUG ABSORPTION; DRUG DISTRIBUTION; DRUG EFFICACY; DRUG ELIMINATION; DRUG EXCRETION; DRUG HALF LIFE; DRUG INHIBITION; DRUG METABOLISM; DRUG STRUCTURE; FATTY LIVER; HEPATITIS; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; IN VITRO STUDY; LACTIC ACIDOSIS; LIPODYSTROPHY; MYOPATHY; NONHUMAN; PANCREATITIS; PERIPHERAL NEUROPATHY; PRIORITY JOURNAL; REVIEW; RHABDOMYOLYSIS;

ANIMALIA; HUMAN IMMUNODEFICIENCY VIRUS;

EID: 0036235237     PISSN: 15677249     EISSN: None     Source Type: Journal    
DOI: 10.1016/S1567-7249(02)00003-X     Document Type: Review

References (129)

1. Emerging patterns of heart disease in HIV infected homosexual subjects with and without opportunistic infections; a prospective colour flow Doppler echocardiographic study
2. Acute pancreatitis with severe lactic acidosis in an HIV-infected patient on didanosine therapy
3. Schwann cell mitochondrial alteration in peripheral nerves of rabbits treated with 2′,3′-dideoxycytidine
4. Peripheral neuropathy induced by 2′,3′-dideoxycytidine. A rabbit model of 2′,3′-dideoxycytidine neurotoxicity
5. Mitochondrial schwannopathy and peripheral myelinopathy in a rabbit model of dideoxycytidine neurotoxicity
6. Depletion of muscle mitochondrial DNA in AIDS patients with zidovudine-induced myopathy
7. AZT treatment induces molecular and ultrastructural oxidative damage to muscle mitochondria
8. Temporal trends in the incidence of HIV-1 related neurologic diseases: Multicenter AIDS cohort study, multicenter AIDS cohort study, 1985-1992
9. Incidence of dilated cardiomyopathy and detection of HIV in myocardial cells of HIV-positive patients
10. Mechanism of toxicity of 3′-azido-3′-deoxythymidine. Its interaction with adenylate kinase
11. 3′-Azido-3′-deoxythymidine uptake into isolated liver mitochondria and impairment of ADP/ATP translocator
12. Cellular and mitochondrial toxicity of ziduvodine (AZT), didanosine(ddl) and zalcjtabine(ddC) on cultured human cells
13. 2′,3′-dideoxycytidine (ddC) toxic neuropathy: A study of 52 patients
14. Severe polymyositis-like syndrome associated with zidovudine therapy of AIDS and ARC
15. Oxidative DNA damage in fetal tissues after transplacental exposure to 3′-azido-3′-deoxythymidine (AZT)
16. Fulminant hepatitis with severe lactate acidosis in HIV-infected patients on didanosine therapy
17. Persistant mitochondrial dysfunction and perinatal exposure to antiretroviral nucleoside analogues
18. Hepatic steatosis and lactic acidosis caused by stavudine in an HIV-infected patient
19. Lactic acidosis (LA) in patients receiving nucleoside reverse transcriptase inhibitors(NRTIs)
20. Favorable interaction of B-L(-) nucleoside analogues with clinically approved anti-HIV nucleoside analogues for the treatment of human immunodeficiency
21. Hyperlactemia and hepatic steatosis as features of mitochondrial toxicity of nucleoside analogue reverse transcriptase inhibitors
22. Management of hyperlactatemia: No need for routine lactate measurements
23. Adverse effects of reverse transcriptase inhibitors: Mitochondrial toxicity as common pathway
24. Mitochondrial toxicity induced by nucleoside-analogue reverse-transcriptase inhibitors is a key factor in the pathogenesis of antiretroviral-therapy-related lipodystrophy
25. Randomized trial of additional of lamivudine plus loviride to zidovudine-containing regimens for patients with HIV-1 infection: The Caesar trial
26. Adverse effects of antiretroviral therapy
27. A syndrome of lipodystrophy, lactic acidemia and liver dysfunction associated with HIV nucleoside analogue therapy: Contribution to protease inhibitor-related lipodystrophy syndrome
28. Excess peripheral neuropathy in patients treated with hydroxyurea plus didanosine and stavudine for HIV infection
29. Biochemical pharmacology of (+) and (-)2′,3′-dideoxy-3′-thiacytidine as anti-hepatitis B virus agents
30. Determination of the blood lactate/pyruvate ratio as a noninvasive test for the detection of zidovudine myopathy
31. Zidovudine-induced mitochondrial disorder with massive liver steatosis, myopathy, lactic acidosis and mitochondrial DNA
32. Survival of a human immunodeficiency patient with nucleoside induced lactic acidosis-role of hemodialysis treatment
33. Predominantly sensory neuropathy in patients with AIDS and AIDS related complex
34. Lack of long-term effects of in utero exposure to zidovudine among uninfected children born to HIV-infected women
35. Early features of zidovudine-associated myopathy: Histopathological finding and clinical correlations
36. Heart muscle disease related to HIV infection: Prognostic implications
37. How to manage metabolic complications of HIV therapy: What to do while we wait for answers
38. Reversible cardiac dysfunction associated with zidovudine exposure in HIV-infected children
39. Peripheral neuropathy and antiretroviral drug
40. Mitochondrial myopathy caused by long-term zidovudine therapy
41. Peripheral neuropathy in the acquired immunodeficiency syndrome
42. Randomized double-blind controlled trial comparing combinations of zidovudine plus didanosine or zalcitabine with zidovudine alone in HIV infected individuals
43. Zidovudine compared with didanosine in patients with advanced HIV-1 infection and little or no previous experience with zidovudine
44. Effect of zidovudine and didanosine treatment on heart function in children infected with human immunodeficiency virus
45. Acetylcarnitine deficiency in AIDS patients with neurotoxicity on treatment with antiretroviral nucleoside analogs
46. Ultrastructure of peripheral neuropathy induced in rabbits by 2′,3′-dideoxycytidine
47. Risk factors for dideoxynucleoside-induced toxic neuropathy in patients with the human immunodeficiency virus infection
48. Mitochondrial toxicity and HIV disease
49. Anti-retroviral therapy, insulin resistance and lipodystrophy
50. Implications of the kinetics of zidovudine in the pregnant baboon following oral administration
51. Symptomatic hyperlactataemia: An emerging complication of antiretroviral therapy
52. Fetal patas monkeys sustain mitochondrial toxicity as a result of in utero zidovudine exposure
53. Fetal mitochondrial heart and skeletal muscle damage in erythrocebus patas monkeys exposed in utero to 3′-azido-3-deoxythymidine
54. Zidovudine-associated myopathy
55. Peripheral neuropathy in a cohort of human immunodeficiency virus infected patients: Incidence and relationship to other nervous system dysfunction
56. Zidovudine-associated myopathy
57. Cardiomyopathy associated with antiretroviral therapy in patients with HIV infection: A report of six cases
58. Chronic hyperlactatemia in HIV-infected patients taking antiretroviral therapy
59. Pharmacology of nucleoside and nucleoside reverse transcriptase inhibitor-induced mitochondrial toxcity
60. The PC12 cell as a model for studies of the mechanism of induction of peripheral neuropathy by anti-HIV-1 dideoxynucleoside analogs
61. Effect of 2′,3′-dideoxycytidine on oxidative phosphorylation in the PC12 cell, a neuronal model
62. Relation of peripheral neuropathy to HIV treatment in four randomized clinical trials including didanosine
63. Abnormal skeletal and cardiac muscle mitochondria induced by zidovudine (AZT) in human muscle in vitro and in animal model
64. Cardiomyopathy in AIDS: A pathophysiological perspective
65. Zidovudine causes early increase in mitochondrial ribonucleic acid abundance and induces ultra-structural changes in cultured mouse muscle cells
66. Mitochondrial toxicity of antiviral drugs
67. Mitochondrial toxicity of antiretroviral nucleosides used in AIDS: Insights derived from toxic changes observed in tissues rich in mitochondria
68. Zidovudine induced molecular, biochemical and ultrastructural in rat skeletal muscle mitochondria
69. Cardiac dysfunction occurs in the HIV-1 transgenic mouse treated with zidovudine
70. Combined anti-retroviral therapy causes cardiomyopathy and elevates plasma lactate in transgenic AIDS mice
71. Differential incorporation and removal of antiviral deoxynucleotides by human DNA polymerase-gamma
72. Dilated cardiomyopathy in HIV-infected patients
73. Cardiac structure and function in children with human immunodeficiency virus infection treated with zidovuine
74. Absence of cardiac toxicity of zidovudine in infant pediatric pulmonary and cardiac complications of vertically transmitted HIV infection study group
75. 'Buffalo hump' in men with HIV-1 infection
76. Hydroxyurea as an inhibitor of human immunodeficiency virus-type 1 replication
77. Lipodystrophy in patients naive to HIV protease inhibitors
78. Light and electron microscopy findings in subcutaneous fat in antiretroviral treated and HIV-infected patients
79. Mitochondrial DNA depletion, assessed by real-time PCR-based quantitative assay, in subcutaneous fat of HIV-infected patients: Evidence for a role in the etiology of fat wasting
80. Skeletal muscle mitochondria from AZT-treated rats have a diminished response to chronic electrical stimulation
81. Hepatic failure and lactic acidosis due to fialuridine (FIAU), an investigational nucleoside analogue for chronic hepatitis B
82. Rhabdomyolysis in antiretroviral therapy with lamivudine
83. Circulating p24 antigen levels and responses to dideoxycytidine in human immunodeficiency virus (HIV) infections
84. Lactic acidosis and hepatic steatosis associated with use of stavudine: Report of four cases
85. Lactic acidosis associated with stavudine administration: A report of five cases
86. Incidence of neuropathy in HIV infected patients on monotherapy versus those on combination therapy with didanosine, stavudine, hydroxyurea
87. Incidence of pancreatitis in HIV-infected patients receiving nucleoside reverse transcriptase inhibitor drugs
88. Lipodystrophy and long-term therapy with nucleoside reverse transcriptase inhibitors
89. Mitochondrial respiratory chain disorders and the liver
90. Clinical manifestations and management of anti-retroviral nucleoside analog-related mitochondrial toxicity
91. Database for anti-HIV compounds
92. Massive hepatic steatosis and lactic acidosis in a patient with AIDS who was receiving zidovudine
93. Transpacental effects of 3′-azido-3′-deoxythymidine (AZT): Tumorigenicty in mice and genotoxcity in mice and monkeys
94. Incorporation of zidovudine into leukocyte DNA from HIV-1-positive adults and pregnant women, and cord blood from infant exposed in utero
95. Transplacental pharmakinetics and fetal distribution of 2′,3′-dehydro-3′-deoxythymidine (d4T) and its metabolites in late term rhesus macaques
96. Temporal development of 2′,3′-dideoxyinosine (ddI)-induced peripheral myelinopathy
97. Incorporation of 3′-azido-3′-deoxythymidine (AZT) into fetal DNA and fetal tissue distribution of drug after infusion of pregnant late-term rhesus macaques with a human-equivalent AZT dose
98. Genotoxic risks of perinatal exposures to antiretroviral reverse transcriptase inhibitors (NRTIs)
99. Increased incidence of peripheral neuropathy with co-administration of stavudine and isoniazid in HIV-infected individuals
100. Frequency and factors associated with cardiomyopathy in patients with human immunodeficiency virus infection in an inner-city hospital
101. A syndrome of peripheral fat wasting (lipodystrophy) in patients receiving long-term nucleoside analogue therapy
102. Antiretroviral therapy
103. Rates and risk factors for adverse events associated with didanosine in the expanded access program
104. Evaluation of brain and nerve pathology in rats chronically dosed with DDI or isoniazid
105. Effect of L-carnitine on the zidovudine-induced destruction of human myotubes. Part 1: L-carnitine prevents the myotoxicity of AZT in vitro
106. Effect of L-carnitine on the zidovudine-induced destruction of human myotubes. Part 2: Treatment with L-caritine improves the AZT-induced changes and prevents further destruction
107. Lactic acidosis in the setting of antiretroviral therapy for the acquired immunodeficiency syndrome
108. Mitochondrial DNA decrease in subcutaneous adipose tissue of HIV infected individuals with peripheral lipoatrophy
109. Myopathies associated with human immunodeficiency virus and zidovudine: Can their effects be distinguished?
110. Metabolic abnormalities in skeletal muscle of patients receiving zidovudine therapy observed by P31 in vivo magnetic spectroscopy
111. Cardiac complications in children with human immunodeficiency virus infection
112. 3′-Azidothymidine significantly alters glycosphingolipid synthesis in melanoma cells and decreases the shedding of gangliosides
113. Biochemistry
114. Hepatotoxicity associated with antiretroviral therapy in adults infected with human immunodeficiency virus and the role of hepatitis C or B virus infection
115. Role of reactive oxygen species and poly-ADP-ribose polymerase in the development of AZT-induced cardiomyopathy in rats
116. Fat distribution in AIDS
117. Myopathy with human immuno-deficiency virus type 1 (HIV-1) infection: HIV-1 or zidovudine?
118. Effect of anti-HIV 2′-beta-fluoro-2′,3′-dideoxynucleooside analogs on the cellular content of mitochondrial DNA on lactate production
119. Increased risk of lipodystrophy when nucleoside analogue reverse transcriptase inhibitors are included with protease inhibitors in the treatment of HIV-1 infection
120. Lipodystrophy in HIV-1-positive patients is associated with insulin resistance in multiple metabolic pathways
121. Antiretroviral drug trials
122. Fulminant neuropathy and lactic acidosis associated with nucleoside analog therapy
123. Decrease of mitochondrial DNA content in adipose tissue of HIV-1 infected patients treated with NRTIs
124. Mitochondrial diseases in man and mouse
125. P magnetic resonance spectroscopy suggests impaired mitochondrial function in AZT-treated HIV-infected patients
126. Frequency of left ventricular dysfunction and other echocardiographic abnormalities in human immunodeficiency virus seronegative intravenous drug users
127. HIV associated peripheral neuropathy: Epidemiology pathophysiology, and treatment
128. 3′-Azidothymdine (zidovudine) inhibits glycosylation and dramatically alters glycosphingolipid synthesis in whole cells at clinically relevant concentrations
129. Cytochrome c oxidase deficiency in the muscle of patients with zidovudine myopathy is segmental and affects both mitochondrial DNA and nuclear DNA encoded subunits